Literature DB >> 11167127

Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.

E Becker1, D R Richardson.   

Abstract

Friedreich's ataxia (FA) is a severe neurodegenerative condition with an incidence of 1:50000 in the European population. In 97% of patients this disease is due to an intronic GAA triplet repeat expansion in the FRDA gene resulting in a marked decrease in its expression. The protein encoded by this gene is known as frataxin which is found within the mitochondrion. Upon deletion of the homologous gene (YFH1) in the yeast, there was an accumulation of iron (Fe) within the mitochondrion. When the YFH1 gene was reintroduced back into the yeast cell Fe was exported out of the mitochondrion and into the cytosol. Evidence that human frataxin is also involved in mitochondrial Fe-overload comes from studies in FA patients that have shown an accumulation of Fe within the heart. While the precise role of human frataxin remains to be determined, the molecule appears to be involved indirectly in regulating the export and/or import of mitochondrial Fe. The finding of mitochondrial Fe-overload suggests that the use of specific Fe chelators which can permeate the mitochondrion may have potential in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167127     DOI: 10.1016/s1357-2725(00)00067-4

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

1.  HSC20 interacts with frataxin and is involved in iron-sulfur cluster biogenesis and iron homeostasis.

Authors:  Yuxi Shan; Gino Cortopassi
Journal:  Hum Mol Genet       Date:  2011-12-13       Impact factor: 6.150

Review 2.  The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.

Authors:  Des R Richardson; Michael L-H Huang; Megan Whitnall; Erika M Becker; Prem Ponka; Yohan Suryo Rahmanto
Journal:  J Mol Med (Berl)       Date:  2009-12-09       Impact factor: 4.599

3.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  The iron chaperone poly(rC)-binding protein 2 forms a metabolon with the heme oxygenase 1/cytochrome P450 reductase complex for heme catabolism and iron transfer.

Authors:  Izumi Yanatori; Des R Richardson; Shinya Toyokuni; Fumio Kishi
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

5.  Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region.

Authors:  Ana R Correia; Tao Wang; Elizabeth A Craig; Cláudio M Gomes
Journal:  Biochem J       Date:  2010-02-09       Impact factor: 3.857

6.  Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.

Authors:  Timothy B Chaston; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2003-02-05       Impact factor: 3.358

Review 7.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

8.  Temporal but not spatial dysmetria relates to disease severity in FA.

Authors:  Manuela Corti; Agostina Casamento-Moran; Stefan Delmas; Samantha Bracksieck; Jessica Bowman; Blake Meyer; Samantha Norman; Sub Subramony; Evangelos A Christou
Journal:  J Neurophysiol       Date:  2019-11-06       Impact factor: 2.974

9.  A Potential New Therapeutic Approach for Friedreich Ataxia: Induction of Frataxin Expression With TALE Proteins.

Authors:  Pierre Chapdelaine; Zoé Coulombe; Amina Chikh; Catherine Gérard; Jacques P Tremblay
Journal:  Mol Ther Nucleic Acids       Date:  2013-09-03       Impact factor: 10.183

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.